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Abstract
Background: The CloneSelect™ Imager system is an image-based visualisation system for cell growth assessment. 
Traditionally cell proliferation is measured with the colorimetric MTT assay.
Results: Here we show that both the CloneSelect Imager and the MTT approach result in comparable EC50 values 
when assaying the cytotoxicity of cisplatin and oxaliplatin on various cell lines. However, the image-based technique 
was found non-invasive, considerably quicker and more accurate than the MTT assay.
Conclusions: This new image-based technique has the potential to replace the cumbersome MTT assay when fast, 
unbiased and high-throughput cytotoxicity assays are requested.
Background
High-throughput screening methods for toxicology eval-
uation in the early phases of drug discovery are highly
desired. In the early 1980´s a novel assay for cell survival
determination was reported [1], which has been fre-
quently used to study the biological activity of a variety of
potential cytostatic drugs. The assay was presented as a
rapid, precise and simple method to detect living cells in
mammalian cell cultures, using the tetrazolium salt MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide) and a microtiter plate reader. The MTT is
reduced in living cells, forming formazan crystals which
are then dissolved in a mixture of HCl and isopropanol
[1], or alternatively in dimethylsulfoxide [2]. The optical
d e n s i t y  o f  d i s s o l v e d  c r y s t a l s  i s  t h e n  r e a d  i n  e a c h  w e l l
within the first hour. Cell survival is determined after the
data analysis [1]. Although widely used, the MTT assay
has several disadvantages: in particular poor linearity
with the cell number, sensitivity to environmental condi-
tions and more importantly the dependence of cell
metabolism on formazan [3-5]. These observations have
lead to a search for different alternative assays, such as
the measurement of cellular protein content with the SRB
dye (Sulforhodamine B) [4,6,7] and a variety of other in
vitro assays [8]. However, the SRB assay requires a time-
consuming workout, such as incubation with the dye for
30 min and fixation. A faster and more reliable system
able to screen large number of potential compounds in a
large panel of cells would therefore be considered an
enormous improvement in the pharmacology research.
The CloneSelect™ Imager (Genetix Limited, New Mil-
ton,[9]) could offer such an opportunity. The system was
designed to be capable of screening cellular confluence
and growth in a range of microwell plates. For these mea-
surements, the first step consists on a calibration of the
cell number in the microtiter plates in used, and for each
cell type. After this step, the cells will be counted based
on such calibration. Cell growth is viewed and tracked in
every well, using label-free white light imaging for consis-
tent determination of cell confluence and cell number
estimation. Therefore, from such measurements the con-
fluence in each well can be determined rapidly and effi-
ciently. The CloneSelect Imager system captures images
of the entire well, which provides a label-free, non-
destructive and direct analysis of the cell proliferation in
each well as function of time. Moreover, the imaging of a
96 well plate is extremely fast, with the data acquisition in
less than 3 min. Data can be either output into a spread
sheet, or displayed visually as a series of pie charts.
The present study attempts to validate the CloneSelect™
Imager system for use in cellular toxicity screening of
platinum-based drugs. Two different drugs have been
selected for this study, namely the well-known cisplatin
and oxaliplatin in two different human cancer cell lines. A
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comparison is made between the MTT assay results and
the results obtained using the CloneSelect Imager system
using a Bland-Altman plot [10].
Our results unequivocally show that the CloneSelect™
Imager system offers a superior and rapid alternative in
determining the cytotoxicity of different agents on both
adherent and non-adherent cell lines.
Results and discussion
Plates were treated with the antiproliferative agents,
imaged with the CloneSelect Imager system 24 h, 48 h
and 72 h after the addition of the agents. To compare with
the MTT assay, once the plate was imaged with the Clo-
neSelect Imager system, the MTT assay was performed;
therefore, the results from the CloneSelect™ Imager and
the MTT assay originate from the same plate and there-
fore are directly comparable. The well-known human
ovarian carcinoma cisplatin-sensitive A2780 cells and the
cisplatin-resistant counterpart A2780R cells were
selected as adherent cells. The cytotoxic activity of cispla-
tin and oxaliplatin has been investigated in parallel cul-
tures under the same conditions in a pair of human
ovarian carcinoma cell lines (i.e. the A2780 and the
A2780R cells). The incubation with the platinum(II) com-
pounds can be followed using the CloneSelect Imager
system, obtaining a rapid view of the antiproliferative
activity of the compounds in the cells over the time (See
Additional file 1, Figure S1). The cell confluence (%) in
the wells versus time of incubation (h) with the cisplatin
in the A2780R cells is shown in Figure 1.
The compound was added to the cells in different con-
centrations to achieve a dose-response curve. The
A2780R cells were still growing 24 h after the addition of
the compounds (Figure 1); therefore, the determination
of the EC50 value was not performed in this case. This
observation is important, since the EC50 value after 24 h
of incubation with cisplatin in the A2780 cell line has
been reported [11-13]. The same plate after 48 h of incu-
bation with the platinum(II) compound shows significant
changes. The cells incubated with higher concentrations
show a lack of growth, while the cells incubated with
lower concentrations show a growth comparable to the
non-treated cells. The growth inhibition of the cells is
even more evident in the wells with highest concentration
of the platinum compound when the same plate is imaged
after 72 h of incubation, while the growth continue in the
wells with lower concentrations of the antiproliferative
agent. Similar results were obtained for cisplatin incuba-
tion in the A2780 cells (See Additional file 2, Figure S2),
as also observed for the incubation with oxaliplatin (data
not shown).
Cell confluence (%) is also displayed directly with the
CloneSelect Imager system, as depicted in Figure 2,
where the two first columns (1 and 2) of the microtiter
plate were non-treated cells. In addition, the plate was
divided to incubate the A2780R cells with both cisplatin
and oxaliplatin, as described in the experimental section,
using ten different concentrations. Figure 2 clearly shows
that the CloneSelect Imager system provides a rapid
insight into the different cytotoxic activities displayed by
both platinum drugs against the cells under study. The
A2780R cells were treated with the same concentrations
of cisplatin and oxaliplatin, confirming that oxaliplatin is
more cytotoxic than cisplatin in the A2780R cells. Similar
results as for the cytotoxicity of oxaliplatin in the A2780R
cells were observed in the A2780 cells (see Additional file
3: Figure S3).
Moreover, it is important to mention that a different
sensitivity of the A2780R cells against cisplatin was
observed, compared to the sensitivity of the A2780 cells.
For instance, in Figure 2 the non-treated A2780R cells
have a 55% confluence, while a 33% of confluence is
observed when the cells are incubated with 6.17 μM of
cisplatin. In the case of A2780 cells (see Figure S3) the
sensitivity to the drug is higher, finding a 15% of conflu-
ence after 72 h of incubation with 6.17 μM cisplatin (non-
treated cells 40%).
Comparison of cytotoxicity determined by CloneSelect™ 
Imager system and the MTT assay
To compare the cytotoxicity results observed with the
CloneSelect™ Imager system and the MTT assay, the
agreement between the pEC50 values obtained using both
methods can be calculated, using the so-called Bland-Alt-
man plot [10]. For a comparison between the MTT assay
and the SRB assay such a Bland-Altman plot was reported
earlier [4], showing that the results obtained with the SRB
assay displayed a good agreement with the MTT assay
results. By plotting the difference between the pEC50 val-
ues determined by each of the methods against the mean
Figure 1 Cell confluence (%) vs incubation time with cisplatin in 
the A2780R cells; only results of six wells are plotted for clarity.Marqués-Gallego et al. BMC Biotechnology 2010, 10:43
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of the two determinations it is possible to determine the
agreement between both methods [10]. Therefore, to
compare the two methods, a Bland-Altman analysis of
the pEC50 values, obtained using the MTT assay and the
CloneSelect™ Imager system, has been performed. For
example, the Bland-Altman plot of cisplatin after 48 h of
incubation in both the A2780 (Figure 3A) and the
A2780R cells (Figure 3B) shows that there is a good agree-
ment between the two variables, where all the data points
are within the limits of agreement.
The limits of agreement are also calculated to give a
quantitative analysis of the differences between both
methods after 48 h and 72 h of incubation with cisplatin
and oxaliplatin (Table 1). These results demonstrate that
Figure 3 Bland-Altman plot (pEC50 value difference CloneSelect Imager-MTT vs average) showing the comparison of the pEC50 values pro-
duced by cisplatin in: (A) the A2780 cells, (B) the A2780R cells, after 48 h of incubation, tested with CloneSelect Imager system and MTT 
assay. The limits of agreement (bias ± 1.96 SD) are denoted with horizontal solid lines.
Figure 2 Cell confluence (in %) of the A2780R cells treated with cisplatin (rows from A to D), or oxaliplatin (rows from E to H) after 72 h of 
incubation. First two columns (1 and 2) are non-treated cells. The compounds concentration is increasing from well 3 to well 12 (from the left to the 
right: 8.47 nM, 25.4 nM, 76.2 nM, 0.229 μM, 0.686 μM, 2.06 μM, 6.17 μM, 18.5 μM, 55.6 μM, and 167 μM).Marqués-Gallego et al. BMC Biotechnology 2010, 10:43
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the pEC50 values obtained with the CloneSelect™ Imager
system and the MTT assay are in close agreement. These
observations clearly show that the CloneSelect Imager
system is a very good alternative to the colorimetric assay
to determine the antiproliferative activity of different
drugs.
In order to estimate the cytotoxic activity of the plati-
num compounds measured with the CloneSelect Imager,
the data analysis using the non-treated cells as 100% via-
ble cells at the end of the assay was performed. From
independent measurements preformed using MTT and
CSI it is noted that the MTT assay shows larger intra-
experimental deviations than the CloneSelect Imager sys-
tem (note the smaller error bars when CloneSelect
Imager is used). For instance, the dose-respond plots for
cisplatin incubation after 72 h in the A2780R cells (Figure
4A) show larger deviations within the data using the
MTT assay than when using the CloneSelect Imager sys-
tem (Figure 4B). The reproducibility is quite good when
CSI is used, as shown by the small errors bars in the fig-
ure. However, larger deviations are observed for the MTT
assay, as the number of viable cells increases and could
account for often observed the poor linearity of the MTT
assay with the cell number at high cell densities [14,15].
Similar results have been observed when the A2780 cells
are incubated with cisplatin (data not shown).
Cytotoxic activity in mice leukemia cells using CloneSelect™ 
Imager system
When using the MTT assay with non-adherent cells the
MTT assay displays a huge disadvantage, since the cul-
ture medium has to be removed to quantify the formazan
crystals at the end of the assay. Consequently, the last step
in the protocol for the MTT assay results in the loss of
crystals, and therefore, in large errors.
An improved colorimetric assay for non-adherent cells
was introduced [16,17], using the substrate 5-(3-car-
boxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)3-(4-sul-
fophenyl) tetrazolium (known as MTS), where the
formazan product is soluble in the cell culture medium;
however, unreliable results from the MTS assay in the
L1210 cell line have been reported [18].
As a result of the difficulties of measuring cell cytotox-
icity in non-adherent cells the CloneSelect Imager system
was tested to determine if it was advantageous in this
case. This study was undertaken using the known cyto-
toxic activity of cisplatin and oxaliplatin in the L1210/0
and the resistant counterpart L1210/2 cells. These cell
lines are generally slightly attached to the bottom of the
well, and careful handling of the microtiter plate allows
accurate imaging with the CloneSelect Imager. The
results for the different incubation times are summarized
in Table 2.
As expected, oxaliplatin displays a high cytotoxic activ-
ity against the L1210/0 cells [19], and it is able to over-
come the resistance to cisplatin present in the L1210/2
cells, with no significant differences (p > 0.05) between
the pEC50 values in the L1210/0 and in the L1210/2 cells
for both incubation times. The MTT assay using the mice
leukemia cells could not be performed in this case,
because the last step in the MTT assay requires the dis-
charge of the medium, generating experimental errors
due to the loss of formazan crystals from the non-adher-
ent cells, as mentioned above. This further illustrates the
superiority of the CloneSelect Imager method.
Conclusions
The most commonly used approach to quantify mamma-
lian cell proliferation is the conversion of a tetrazolium
salt (MTT) to the formazan crystals by cellular dehydro-
genases [1]. Nevertheless, the MTT assay is time con-
suming when many samples have to be assayed.
Moreover, the colorimetric assay kits are relatively expen-
sive, and most important, they are destructive, not allow-
ing measurements over time, using the same microtiter
plate. New imaging methods have been introduced more
recently, such as CloneSelect™ Imager. In this study this
new system is compared with the widely used MTT assay,
because - despite its disadvantages - the MTT assay is
largely used in the screening of the antiproliferative effect
Table 1: Comparison of the pEC50 values obtained with the CloneSelect Imager system analysis and the MTT assay.
Cell line/time Mean difference SD Limits of agreement
Compound Mean-2SD Mean+2SD
cisplatin A2780/48 h -0.64 0.24 -1.11 -0.17
A2780R/48 h 0.12 0.08 -0.03 0.27
A2780/72 h -0.26 0.06 -0.36 -0.15
A2780R/72 h 0.08 0.06 -0.04 0.20
oxaliplatin A2780/48 h -0.63 0.39 -1.40 0.13
A2780R/48 h -0.05 0.28 -0.60 0.51
A2780/72 h -0.18 0.22 -0.61 0.26
A2780R/72 h -0.11 0.07 -0.23 0.02Marqués-Gallego et al. BMC Biotechnology 2010, 10:43
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of new compounds. A major advantage of the CloneSe-
lect Imager system, compared to MTT assay, is that
allows a direct screening of the antiproliferative activity
of the drugs in only three minutes, with a direct overview
from the cell confluence (%) after imaging in each well,
not requiring additional steps to obtain these preliminary
data. Additionally, it is possible to image the same plate as
a function of time, based on a non-invasive methodology,
saving in this way time and costs.
In summary, the CloneSelect™ Imager system has been
compared with the MTT assay, and it displays lower intra
experimental deviations in the dose response curves, with
high reproducibility, and showing that the CloneSelect
Imager system is a much preferred alternative to deter-
mine the antiproliferative activity of different drugs and
possibly more accurate.
Methods
Platinum compounds
The platinum compounds cisplatin and oxaliplatin were
purchased from Aldrich. Aliquots of a 2 mM stock solu-
tion of cisplatin and oxaliplatin in 40 mM NaCl were
stored in dark at -20°C, defrosted and diluted with cell
culture medium to the desired concentration before use.
Cell lines, culture conditions
The human ovarian carcinoma cell line A2780 and its cis-
platin-resistant counterpart A2780R, and the cisplatin-
sensitive mouse leukemia L1210/0 and its cisplatin-resis-
tance counterpart L1210/2 were grown in suspension at
37°C in a 7% CO2 atmosphere, and were maintained in a
continuous logarithmic culture in Dulbecco´s modified
Eagle´s Medium (DMEM) (Gibco BRL TM, Invitrogen
Corporation, The Netherlands) supplemented with 10%
heat-inactivated fetal calf serum (Hyclone, Perbio Sci-
ence, The Netherlands), penicillinG Sodium (100 units/
ml: Dufecha, Biochemie BV, The Netherlands), strepto-
mycin (100 μg/ml: Dufecha, Biochemie BV, The Nether-
lands) and Glutamax 100× (Gibco BRL TM, The
Netherlands).
Figure 4 Comparison of the dose response plot of cisplatin after 72 h in the A2780R cells. Both plots display cell viability relative to non-treated 
cells vs -log [cisplatin]. (A) measure with the MTT assay and (B) measure with the CloneSelect Imager system. The pEC50 value is denoted at the crossing 
of the solid lines. The concentration of cisplatin used (8.47 nM, 25.4 nM, 76.2 nM, 0.229 μM, 0.686 μM, 2.06 μM, 6.17 μM, 18.5 μM, 55.6 μM, and 167 μM) 
plotted as -log C vs cell viability. The error bars indicate the accuracy and reproducibility.
Table 2: EC50 (μM) values obtained after 48 h and 72 h incubation with cisplatin and oxaliplatin on the suspension cultures 
L1210/0 and the L1210/2 cells obtained, using the CloneSelect Imager system
compound L1210/0
48 h
L1210/2
48 h
RF* L1210/0
72 h
L1210/2
72 h
RF*
Cisplatin 5.9 36.3 6.2 2.9 18.2 6.3
Oxaliplatin 3.8 5.6 1.5 2.0 1.3 0.7
*RF = resistance factor (EC50 (L1210/2)/EC50(L1210/0)Marqués-Gallego et al. BMC Biotechnology 2010, 10:43
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Cytotoxicity assay
Microtiter plates with ninety six wells were used for the
antiproliferative measurements of cisplatin and oxalipla-
tin. Cultures in the well plates were measured at different
time points, and returned to the incubator. The number
of seeded cells was adjusted according to the incubation
time with the drugs. On day one, 10,000 cell/well for 24 h
incubation assay were seeded, while 5,000 and 3,000 cells/
well were seeded for 48 h and 72 h incubation assay,
respectively. The plates were pre-incubated for 24 h at
37°C, 7% CO2 to allow the human ovarian carcinoma cells
to adhere. In case of the mice leukemia cells, the plates
were also kept for 24 h before the addition of the plati-
num compounds. The L1210/0 and the L1210/2 cells are
in suspension or slightly attached. On day two, the plates
were monitored with the CloneSelect™ Imager system
(Genetix, UK) before the addition of the antiproliferative
agents (cisplatin and oxaliplatin) and returning to the
incubator. A threefold dilution series of ten concentra-
tions of the platinum drugs was made, starting with a 2
mM stock solution of the compounds. For each concen-
tration 50 μL of compound was added to the medium in
triplicate. All time-point experiments were performed in
parallel and were repeated five times, independently to
verify how reproducible the experiments are. To obtain
the antiproliferative data with CloneSelect Imager and
MTT from the same plate at the same time point the
treated microtiter plates were first monitored using Clo-
n e S e l e c t  I m a g e r  s y s t e m  a n d  s u b s e q u e n t l y  5 0  μ L  o f  a
MTT solution (5 mg/ml in PBS buffer) were added to
each well, and the plate kept at 37°C for 3 h to allow for-
m a t i o n  o f  t h e  f o r m a za n  c ry s t a l s  [ 1 ] .  T h e  s o l u t i o n  w a s
then carefully removed and the blue formazan crystals
were dissolved in 100 μL DMSO, and the absorbance was
read at 590 nm using an automatic microplate reader
(Labsystems Multiskan MS) as previously described
[20,21]. In the case of the mice leukemia cells, the plates
were imaged with the CSI system. The data obtained with
CloneSelect Imager assay and with MTT assay were ana-
lyzed and the pEC50 values (EC50 is the drug concentra-
tion that produces 50% of the maximum response) were
determined with the GraphPad Prism™ analysis software
package (GraphPad Software, San Diego, USA) using
non-linear regression (sigmoidal dose response, variable
slope).
Statistical analysis
The comparison of the antiproliferative activity deter-
mined by the two methods (CloneSelect Imager and
MTT) was performed using the Bland-Altman plot [10].
In the cytotoxic activity the Student's t-test was per-
formed for statistical comparison. A p-value < 0.05 was
considered as statistically significant.
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